The board of the directors of Bloomage BioTechnology Corporation Limited announced that, based on the preliminary review and assessment of the latest unaudited consolidated management accounts of the Group, it is expected that the Group will record a year-on-year increase in sales income exceeding 30% for the period ended 31 December 2015, which mainly benefits from the gradual implementation of the products diversification strategy for the medical beauty ecological chain formed by the Group. In order to better implement the products diversification strategy for the medical beauty ecological chain, and keep its leading position in the PRC medical beauty industry and sustainable growth of future results, in 2015, the company has undertaken certain overseas investment and acquisition and financing projects, and entered into agreements to issue management subscription shares to the core management, which incurred a series of extra fees and expenses and accounting impacts, including one-off intermediary expense in respect of investment and acquisition and financial project; equity settled share-based payment expense arising from the management subscription shares to be issued; amortization of intangible assets arising from acquisition projects; interest expenses arising from financing. It is expected that the above expense and accounting impacts in aggregate will exceed RMB 50,000,000.00, which would affect the overall net profits of the company for the financial year ended 31 December 2015.